公司资料
ProQR Therapeutics 股价、新闻与催化剂
- 股票代码:
- PRQR
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Netherlands and listed in the U
股票表现
1.93 USD (+0.52%)
收盘价
最后更新: 2026年8月17日
155M USD
市值
股价为何变动
As of Aug 17, 2026, PRQR closed up 0.52% at $1.93. No new same-company headline was identified in the current news window.
公司概览
RNA Editing Company
ProQR Therapeutics develops RNA-editing medicines using its Axiomer platform.
Axiomer Technology
Axiomer recruits endogenous ADAR enzymes to make precise single-base changes in RNA without permanently altering DNA.
AX-0810
AX-0810 targets NTCP and is being developed initially for biliary atresia, with early clinical work measuring target engagement in healthy volunteers.
Pipeline Expansion
Additional programs include AX-0811 and IDUA-targeting AX-0422, supported by internal and partnered discovery capabilities.
未来催化剂
- Full Phase 1 dataset for AX-0810 at a medical or scientific conference later in 2026.
- Initial Phase 1 data for AX-0811 by the end of 2026.
- Initiation and initial data from the biliary-atresia investigator study in the first half of 2027.
- Initial patient data for AX-0422 in MPS I Hurler syndrome in the first half of 2027.
- Advancement of AX-2911 into clinical development in the first half of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。